Correction: Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts

Correction to: Molecular Biology Reports (2026) 53:713

10.1007/s11033-026-11891-y

In the original publication, Figs. 1, 2, 3, 4 and 5 were inadvertently interchanged, during production process. While the figure legends remain correct, the images themselves were swapped. The figures with their appropriate legends are presented below.

Fig. 1.

Methodology scheme depicting the three cohorts used in the present study

Fig. 2.

Overall survival (OS) by Kaplan-Meier and log-rank test for OC patients in cohort A, according to HPSE rs4364254 genotype distribution. The C allele carriers showed lower OS compared to TT genotype carriers (CC/CT vs. TT; log-rank test, p = 0.001). The mean OS for C allele carriers was 36.1 ± 4.5 months, while for TT genotype carriers was 59.0 ± 5.2 months

Fig. 3.

Progression-free survival (PFS) and overall survival (OS) by Kaplan-Meier and log-rank test for OC patients in cohort A, according to HPSE rs11099592 genotype distribution. The TT genotype group showed lower survival times compared to C allele carriers. A) The mean PFS for C allele carriers was 28.8 ± 3.3 months, while TT carriers presented a mean PFS of 11.8 ± 3.1 months (CC/CT vs. TT; log-rank test, p = 0.050). B) The mean OS for C allele carriers was 48.9 ± 3.9 months, while for TT genotype carriers the mean OS was 25.4 ± 5.8 months (CC/CT vs. TT; log-rank test, p = 0.025). However, both findings should be evaluated carefully, given the under representation of the TT genotype. The significant results concerning the impact of the SNPs on patients’ prognosis in cohort A were validated in the independent cohort B. While no significant association was detected in the entire cohort B, stratified analyses confirmed the association between the rs4364254 C and rs11099592 T alleles and poorer clinical outcomes. Among the patients resistant to platinum, the rs4364254 Callele was associated with lower OS compared to the TT genotypes (CC/CT vs.TT; mean OS of 19.9 ± 2.4 months and 28.8 ± 3.4 months; log-rank test, p = 0.044; Fig. 4). As for rs11099592, non-serous OC patients carrying the T allele presented a worse OS than their counterparts with the CC genotype (TT/CT vs. CC; mean OS of 45.1 ± 3.3 months and 53.5 ± 1.6 months, respectively; log-rank test, p = 0.016; Fig. 5)

Fig. 4.

Overall survival (OS) by Kaplan-Meier and log-rank test for cohort B platinum-resistant OC patients, according to HPSE rs4364254 genotype distribution. C allele carriers had a worse OS than TT allele carriers (CC/CT vs.TT; log-rank test, p = 0.044). The mean OS for C allele and TT genotype carriers was 19.9 ± 2.4 months and 28.8 ± 3.4 months, respectively

Fig. 5.

Overall survival (OS) by Kaplan-Meier and log-rank test for cohort B non-serous OC patients, according to genotype distribution for HPSE rs11099592. T allele carriers presented a worse OS than CC allele carriers (TT/CT vs. CC; log-rank test, p = 0.016). T allele and CC genotype carriers had a mean OS of 45.1 ± 3.3 months and 53.5 ± 1.6 months, respectively

The original article has been corrected.